Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GP Pharm, S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'GP Pharm, S.A. - Product Pipeline Review - 2014', provides an overview of the GP Pharm, S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of GP Pharm, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of GP Pharm, S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of GP Pharm, S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the GP Pharm, S.A.'s pipeline products Reasons to buy - Evaluate GP Pharm, S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of GP Pharm, S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the GP Pharm, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of GP Pharm, S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of GP Pharm, S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of GP Pharm, S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 GP Pharm, S.A. Snapshot 6 GP Pharm, S.A. Overview 6 Key Information 6 Key Facts 6 GP Pharm, S.A. - Research and Development Overview 7 Key Therapeutic Areas 7 GP Pharm, S.A. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 GP Pharm, S.A. - Pipeline Products Glance 12 GP Pharm, S.A. - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Phase III Products/Combination Treatment Modalities 13 GP Pharm, S.A. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 GP Pharm, S.A. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 GP Pharm, S.A. - Drug Profiles 17 desmopressin acetate 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 leuprolide acetate 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 leuprolide acetate depot 3 months 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 doxorubicin liposomal 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 octreotide acetate LAR 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 octreotide acetate MAR 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 triptorelin depot 1 month 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 triptorelin depot 3 months 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 docetaxel liposomal third generation 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 doxorubicin liposomal third generation 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 gemcitabine liposomal third generation 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 goserelin 3 months depot 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GP-1100 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 GP-1200 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 irinotecan hydrochloride liposomal third generation 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 leuprolide acetate depot 6 months 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Pegylated liposomal doxorubicin 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 risperidone depot 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 GP Pharm, S.A. - Pipeline Analysis 36 GP Pharm, S.A. - Pipeline Products by Target 36 GP Pharm, S.A. - Pipeline Products by Route of Administration 38 GP Pharm, S.A. - Pipeline Products by Molecule Type 39 GP Pharm, S.A. - Pipeline Products by Mechanism of Action 40 GP Pharm, S.A. - Recent Pipeline Updates 41 GP Pharm, S.A. - Dormant Projects 42 GP Pharm, S.A. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables GP Pharm, S.A., Key Information 6 GP Pharm, S.A., Key Facts 6 GP Pharm, S.A. - Pipeline by Indication, 2014 9 GP Pharm, S.A. - Pipeline by Stage of Development, 2014 10 GP Pharm, S.A. - Monotherapy Products in Pipeline, 2014 11 GP Pharm, S.A. - Pre-Registration, 2014 12 GP Pharm, S.A. - Phase III, 2014 13 GP Pharm, S.A. - Phase II, 2014 14 GP Pharm, S.A. - Phase I, 2014 15 GP Pharm, S.A. - Preclinical, 2014 16 GP Pharm, S.A. - Pipeline by Target, 2014 37 GP Pharm, S.A. - Pipeline by Route of Administration, 2014 38 GP Pharm, S.A. - Pipeline by Molecule Type, 2014 39 GP Pharm, S.A. - Pipeline Products by Mechanism of Action, 2014 40 GP Pharm, S.A. - Recent Pipeline Updates, 2014 41 GP Pharm, S.A. - Dormant Developmental Projects,2014 42 GP Pharm, S.A., Other Locations 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
